NCT01641952View on ClinicalTrials.gov

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent

CompletedOBSERVATIONAL
Enrollment

505

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Rituximab

Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.

Trial Locations (1)

020983

Bucharest

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01641952 - An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent | Biotech Hunter | Biotech Hunter